Log in
Pharmacology · Drugs and Prescriptions

Gemfibrozil

Gemfibrozilum

Gemfibrozil (Gemfibrozilum) is a lipid-lowering agent belonging to the fibric acid derivative group (fibrates). The drug regulates metabolic processes, predominantly lowering blood triglyceride levels by activating specific nuclear receptors.

Test your knowledge on this topicAsk the AI
GroupAgents regulating metabolic processes (Fibrates)
TargetPPARα nuclear receptors
Dosage formsTablets (0.45 and 0.6 g), capsules (0.3 g)
Drug interactionCombination with statins is strictly prohibited
How to write a prescription
Rp.: Tab. Gemfibrozili 0,45
D.t.d. N 30
S. Внутрь по 1 таблетке 2 раза в день за 30 минут до еды

Alternative prescription entries: Tabulettas Gemfibrozili 0.45; Caps. Gemfibrozili 0.3; Tab. Gemfibrozili 0.6

Dosage form
Tabs. 0.45 and 0.6 g; caps. 0.3 g
Administration
Orally, 0.3–0.45 g twice daily, 30 min before meals
Group
Agents regulating metabolic processes
4 min readFor medical studentsUpdated 09/24/2026
Material prepared by WhiteCoat Pro editorial team based on platform study guidesReviewed by medical editor: Aulov A. A., general practitioner · 09/24/2026

Place in the classification of lipid-lowering agents

In pharmacological classification, gemfibrozil belongs to fibric acid derivatives. For a comprehensive understanding, it is important to remember that in addition to fibrates, the clinician's arsenal includes other groups: HMG-CoA reductase inhibitors (statins), cholesterol absorption inhibitors (e.g., ezetimibe), bile acid sequestrants (cholestyramine), and nicotinic acid derivatives. While statins primarily block cholesterol synthesis, fibrates have a different site of action and specific clinical profile.

Mechanism of action

The action of gemfibrozil is implemented at the genetic level. The drug acts as an agonist of PPARα nuclear receptors (peroxisome proliferator-activated receptors). By binding to this target, the drug triggers a cascade of biochemical reactions:

  • Stimulation of endothelial lipoprotein lipase expression.
  • Upregulation of Apo A protein synthesis, which is the main structural component of high-density lipoproteins (HDL).
  • Inhibition of hepatic cholesterol synthesis (presumably via inhibition of the enzyme HMG-CoA reductase) and decreased production of very-low-density lipoproteins (VLDL).
  • Increased density of lipoprotein receptors on hepatocyte membranes.
Test your knowledge on the topicTasks from the «Pharmacology» course bank — instant answers and explanations.

Pharmacological effects

Activation of PPARα receptors leads to a marked rearrangement of the patient's lipid profile. The key effect is the acceleration of VLDL and intermediate-density lipoprotein (IDL) catabolism, leading to a potent decrease in triglyceride (TG) levels. The effect on triglycerides is the hallmark of fibrates.

Additional effects include a decrease in "atherogenic" low-density lipoproteins (LDL) and an increase in the concentration of "anti-atherogenic" HDL.

Onset of effect: the action is registered 2–5 days after starting therapy, and the peak therapeutic effect is achieved by the 4th week of regular intake.

Pharmacokinetics

The drug has high bioavailability — about 97% of the active substance is absorbed from the gastrointestinal tract upon oral administration. Peak plasma concentration is reached rapidly, within 1–2 hours. Gemfibrozil is metabolized in the liver, and its half-life ($t_{1/2}$) is 1.5 hours. Elimination is predominantly renal, with up to 70% of the drug excreted unchanged.

Indications for use

In clinical practice, gemfibrozil is prescribed for type II, IV, and V hyperlipoproteinemias (HLP). The drug is the agent of choice when it is necessary to most effectively reduce serum triglyceride levels.

Side effects and contraindications

When prescribing the drug, it is necessary to consider the risks of adverse reactions from various organ systems:

  • Muscular system (critically important): development of myalgia, myopathy, and in rare cases, severe rhabdomyolysis.
  • Gastrointestinal tract and liver: dyspepsia, risk of cholestasis.
  • Central nervous system: headache, transient blurred vision.

Dangerous drug interaction: Gemfibrozil is an inhibitor of the hepatic transporter OATP1B1. This protein is responsible for the uptake of statins by hepatocytes. When used concurrently, gemfibrozil blocks this transporter, leading to two fatal consequences:

  1. Decreased therapeutic effect of statins (they do not penetrate the liver where they are supposed to work).
  2. Sharp increase in systemic toxicity (statins accumulate in the blood and damage muscle tissue).

For this reason, combining gemfibrozil with statins is strictly prohibited — the risk of additive side effects and the development of severe myopathy is too high.

Briefly: answers to topical questions

What are the absolute contraindications for prescribing gemfibrozil?

Strict limitations for prescribing gemfibrozil include:

  • Statins — combination is prohibited due to the risk of additive side effects on muscle tissue and the development of severe myopathies.
  • Selexipag — concurrent use is strictly contraindicated, as it leads to a twofold increase in blood selexipag concentration and amplification of its side effects.

With which drugs, besides statins, does gemfibrozil enter into clinically significant interactions?

In addition to statins, gemfibrozil has a clinically significant interaction with selexipag, a drug used to treat pulmonary arterial hypertension.

  • Selexipag — gemfibrozil is a CYP2C8 inhibitor. Concurrent use leads to a twofold increase in blood selexipag concentration and an intensification of its side effects, making it strictly contraindicated.
How to memorize

Fibrates are triglyceride "incinerators". They activate PPARα to clear fat, but they can also "burn" muscles (myopathy), especially if the liver is blocked for statins.

Class and exam questions

Why is gemfibrozil strictly contraindicated for co-administration with statins?

Gemfibrozil inhibits the OATP1B1 transporter, disrupting hepatic uptake of statins. This leads to the accumulation of statins in the systemic circulation and a sharp increase in the risk of severe myopathies and rhabdomyolysis.

Which lipid profile parameter do fibrates reduce most effectively?

Fibrates, including gemfibrozil, most effectively reduce triglyceride (TG) levels by accelerating the catabolism of VLDL and IDL.

Through which receptors does the mechanism of action of gemfibrozil occur?

The drug is an agonist of PPARα nuclear receptors (peroxisome proliferator-activated receptors).

Something unclear? Ask the AIThe AI tutor has reviewed the material on "Gemfibrozil" and will explain it in simple terms.

What else to study on this topic

  • Comparative pharmacokinetics of fibrates: gemfibrozil, fenofibrate, and ciprofibrate.
  • The role of the OATP1B1 transporter in drug metabolism.
  • Pathophysiology of rhabdomyolysis during lipid-lowering therapy.
  • Classification of hyperlipoproteinemias (types II, IV, V) and treatment selection algorithms.
  • HMG-CoA reductase inhibitors (statins) and their place in the treatment of atherosclerosis.

Master the entire topic in the «Pharmacology» course

This is a summary. The course covers everything tested in classes and exams.

  • Complete study guide on "Gemfibrozil" and 5,304 more pages of the subject
  • Assignments and quizzes after every topic — just like in a colloquium
  • AI tutor answers questions on the topic anytime
  • 116 video lessons on the subject
Open full reviewSubject curriculumfrom 599 ₽ per month

Other topics in the «Drugs and Prescriptions» section

Atropine sulfateAceclidineAeronHexoprenalinePirenzepineIpratropium bromideXylometazolineMetocinium iodideNaphazolineNeostigmineNorepinephrinePipecuronium bromidePlatyphyllineSalmeterolSuxamethoniumTropicamideFenoterolEpinephrineEphedrine hydrochlorideAcetaminophenBromocriptineSodium valproateDiazepamZolpidem
The entire "Drugs and Prescription" section

Free video lessons: pharmacologyShort lessons with study notes — no registration required.

Watch lessons

Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.